Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.

There was an interesting trend where the use of anti-rheumatic therapy, primarily hydroxychloroquine in our cohort, was associated with a higher risk of a novel irAE presentation and perhaps a lower risk of a rheumatologic disease flare.

also in 1,783 other papers